دورية أكاديمية
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
| العنوان: | Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer |
|---|---|
| المؤلفون: | Sherman, Scott K., Lange, Joel J., Dahdaleh, Fadi S., Rajeev, Rahul, Gamblin, Clark, Polite, Blase N., Turaga, Kiran K. |
| المصدر: | School of Medicine Publications and Presentations |
| بيانات النشر: | ScholarWorks @ UTRGV |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Medicine and Health Sciences |
| الوصف: | Key Points Question For metastatic colorectal cancer, what is the incremental cost-effectiveness of adding capecitabine and bevacizumab maintenance treatment after standard induction chemotherapy? Findings This economic evaluation study finds that compared with observation, capecitabine and bevacizumab maintenance therapy adds average per-patient benefits of 0.14 quality-adjusted life-years (QALYs), with incremental costs of $105 217 and an incremental cost-effectiveness ratio of $725 601 per QALY. To reduce the cost to $59 039 per unadjusted life-year (median household income) total drug costs must be reduced from $6173 to $452 per 3-week chemotherapy cycle. Meaning High US drug prices represent the best target for improving the cost-effectiveness of capecitabine and bevacizumab maintenance therapy for metastatic colorectal cancer, which is not currently cost-effective. Go to: Abstract Importance Unregulated drug prices increase cancer therapy costs. After induction chemotherapy, patients with metastatic colon cancer can receive maintenance capecitabine and bevacizumab therapy based on improved progression-free survival, but whether this treatment’s cost justifies its benefits has not been evaluated in the United States. Objective This study sought to determine the influence of capecitabine and bevacizumab drug prices on cost-effectiveness from a Medicare payer’s perspective. Design, Setting, and Participants The incremental cost-effectiveness of capecitabine and bevacizumab maintenance therapy was determined with a Markov model using a quality-of-life penalty based on outcomes data from the CAIRO phase 3 randomized clinical trial (RCT), which included 558 adults in the Netherlands with unresectable metastatic colorectal cancer who had stable disease or better following induction chemotherapy. The outcomes were modeled using Markov chains to account for patients who had treatment complications or cancer progression. Transition probabilities between patient states were determined, and each state’s costs were ... |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://scholarworks.utrgv.edu/som_pub/877Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440196/#:~:text=This%20economic%20evaluation%20study%20finds,of%20%24725%20601%20per%20QALYTest. |
| DOI: | 10.1001/jamaoncol.2018.5070 |
| الإتاحة: | https://doi.org/10.1001/jamaoncol.2018.5070Test https://scholarworks.utrgv.edu/som_pub/877Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440196/#:~:text=This%20economic%20evaluation%20study%20finds,of%20%24725%20601%20per%20QALYTest. |
| رقم الانضمام: | edsbas.F799732D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1001/jamaoncol.2018.5070 |
|---|